Histological advantages of the tumor graft: A murine model involving transplantation of human pancreatic cancer tissue fragments

Pancreas

Volumn 42, Issue 8, 2013, Pages 1275-1282

  Akashi, Yoshimasa ^a   Oda, Tatsuya ^a   Ohara, Yusuke ^a   Miyamoto, Ryoichi ^a   Hashimoto, Shinji ^a   Enomoto, Tsuyoshi ^a   Yamada, Keiichi ^a   Kobayashi, Akihiko ^a   Fukunaga, Kiyoshi ^a   Ohkochi, Nobuhiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

animal model; desmoplasia; drug delivery; pancreatic cancer; tumor graft; vascularization

Indexed keywords

DOXORUBICIN; LIPOSOME;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GRADING; CANCER GRAFT; CANCER MORPHOLOGY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CANCER TRANSPLANTATION; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIPOSOMAL DELIVERY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD31; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; MIDDLE AGED; PANCREAS; PANCREAS TRANSPLANTATION; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84887286241     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318296f866     Document Type: Article

References (42)

1. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247Y250.
2. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457Y1461.
3. Huynh AS, Abrahams DF, Torres MS, et al. Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One. 2011;6(5):e20330. Doi: 10.1371/ journal.pone.0020330. Epub 2011 May 27.
4. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455Y465.
5. Hetzel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218Y1249.
6. Jemal CA, Bray F, Center MM, et al. Global cancer statistics. CACancer J Clin. 2011;61:69Y90.
7. Bruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer. 2002;102:101Y108.
8. Shimamura T, Royal RE, Kioi M, et al. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res. 2007;67:9903Y9912.
9. Verma A, Guha S, Diagaradjane P, et al. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008;14:2476Y2483.
10. Duan JX, Jiao H, Kaizerman J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008;51:2412Y2420.
11. Merisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008;7:829Y840.
12. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424Y1431.
13. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003;9:4227Y4239.
14. Povlsen CO, Skakkebaek NE, Rygaard J, et al. Heterotransplantation of human foetal organs to the mouse mutant nude. Nature. 1974;248:247Y249.
15. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992;89: 5645Y5649.
16. Hahn SA, Seymour AB, Hoque AT, et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 1995;55:4670Y4675.
17. Reyes G, Villanueva A, Garcia C, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 1996;56:5713Y5719.
18. Capella G, Farre L, Villanueva A, et al. Orthotopic models of human pancreatic cancer. Ann N Y Acad Sci. 1999;880:103Y109.
19. Tarafa G, Villanueva A, Farre L, et al. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene. 2000;19:546Y555.
20. Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007;67:32Y40.
21. Hylander BL, Pitoniak R, Penetrante RB, et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med. 2005;3(1):22.
22. Garrido-Laguna I, Uson M, Rajeshkumar NV, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011;17:5793Y5800.
23. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 2002;99:4100Y4108.
24. Smith V, Writh GJ, Fiebig HH, et al. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomic Proteomics. 2008;5:263Y273.
25. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer. 2004; 40: 802Y820.
26. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928Y940.
27. Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res. 2010;16:1442Y1451.
28. Hidalgo M, Brunckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10:1311Y1316.
29. MorelliMP, Calvo E, Ordonez E, et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol. 2012;30(4):e45-e48. Doi: 10.1200/JCO.2011.36.9678. Epub 2011.
30. Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441Y1454.
31. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583Y592.
32. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653Y664.
33. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst. 1989;81:1484Y1488.
34. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891Y896.
35. BaxterLT, JainRK.Transport of fluid andmacromolecules in tumors.Role of heterogeneous perfusion and lymphatics. Microvasc Res. 1990;40:246Y263.
36. Baish JW, Gazit Y, Berk DA, et al. Role of tumor vascular architecture in nutrient and drug delivery; an invasion percolation-based network model. Microvasc Res. 1996;51:327Y346.
37. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994;144: 1188Y1194.
38. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883Y893.
39. Bernsen HJ, Rijken PF, Oostendorp T, et al. Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br J Cancer. 1995;71:721Y726.
40. Schultz-Hector S, Kummermehr J, Suit HD. Vascular architecture of experimental tumoursVinfluence of tumour volume and transplantation site. Int J Radiat Biol. 1991;60:101Y107.
41. Hilario E, Rodeno E, Simon J, et al. Differential uptake of systemic fluorochrome Hoechst 33342 in lung and liver metastasis of B16 melanoma. Virchows Arch A Pathol Anat Histopathol. 1992;421:485Y490.
42. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1:78Y82.